Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)

Launched by NYU LANGONE HEALTH · Apr 10, 2019

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing total shoulder arthroplasty;
• • Patients who consent to be randomized.
• Exclusion Criteria:
• • Patients younger than 18 and older than 75;
• • Patients with a history of chronic pain that have used opioids for pain management for 3 months or longer;
• • Patients who are allergic to oxycodone;
• • Patients who are unable to speak English;
• • Patients with diagnosed or self---reported cognitive dysfunction;
• • Patients with a history of neurologic disorder that can interfere with pain sensation;
• • Patients with a history of drug or recorded alcohol abuse;
• • Patients who are unable to understand or follow instructions;
• • Patients with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease;
• • Patients with an allergy or contraindication to any of the medications used in the study, or patients with a contraindication to any study procedures;
• • Patients with BMI over 40;
• • Any patient that the investigators feel cannot comply with all study related procedures;
• • NYU Langone Health students, residents, faculty or staff members